Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

ent. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials.

Participants in the MERLIN TIMI-36 study received modern therapy, with approximately 96 percent of patients on aspirin, approximately 89 percent on beta blockers and approximately 82 percent on statins. Approximately 59 percent of study participants received coronary angiography during their initial hospitalization.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to clinical trials and regulatory filings, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced the ... Intelligence®, the company,s panomic, comprehensive tumor profiling service, ... rare and difficult to treat gynecological cancers may ... to improve patient outcomes. These studies were presented ... of Gynecologic Oncology (SGO) 2015 Annual Meeting on ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/29/2015)... NJ (PRWEB) March 29, 2015 As ... deadlines often required by our pharmaceutical manufacturing clients, Whitehouse ... its sponsorship of the Berkenstock Race Team for the ... requires not only speed, but a strong sense of ... principles that lead to success in the quality control ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... Pharmasset, Inc.,(Nasdaq: VRUS ) announced today that its ... Conference being held from September 24 - 27,2007 in ... Chief,Executive Officer, will provide an overview of the company ... To access a simultaneous webcast of the presentation via ...
... Studies Demonstrate Activity of ... Gram-Positive Bacteria, CHICAGO, Sept. 18 Astellas ... ) announced today results with the,investigational compound telavancin ... skin structure infections,(cSSSIs) from a controlled Phase 3 ...
... /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today announced additional ... 43rd Scientific Sessions of the European Association ... Phase II meal study data was disclosed ... and pharmacodynamics of,insulin VIAject(TM), insulin lispro and ...
Cached Biology Technology:Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 6Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Spanish . ,The oil spill from ... to the ecosystems in the Bay of Biscay. A PhD ... studied the consequences of this spill for the mussels inhabiting ... of the PhD thesis is the biologist Ms Larraitz Garmendia ...
... Norway MA Current research describes a new method ... onset of symptoms. The related report by Zangani et ... NF-κB activation reveals pathology in multiple organ systems," appears ... Journal of Pathology . Autoimmune diseases such as ...
... Germ cells, the cells which give rise to a ... rate of spontaneous point mutations than adult somatic cells, which ... organs. Despite their comparatively higher mutation rates, however, adult ... cloning process called somatic cell nuclear transfer (SCNT). This ...
Cached Biology News:The Prestige oil spill caused changes in the cell structure of mussels 2Stopping autoimmunity before it strikes 2Therapeutic cloning gets a boost with new research findings 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
... 4100 high pressure dual piston pump and the ... and utra low drift. The WaveQuest ... detection and provides superior stability. Hence ... and for monitoring to the highest of sensitivities. ...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
Biology Products: